Back to search

Article

Safety of rituximab biosimilar (Riximyo®) following a single switch from the reference product in patients with Non-Hodgkin’s Lymphoma: A Retrospective Study

2024-04-30

Abstract excerpt

<title>Abstract</title> <p><bold>Introduction</bold>: Unlike small molecule drugs and generic products, the active component of biologics and biosimilars are not identical chemical entities. Despite bioequivalence, there is limited evidence in clinical practice (i.e. Phase IV post-marketing surveillance) regarding the safety of biosimilar rituximab and even less so for “switching therapy” with respect to safety,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
923ce35a-6313-58d3-ae96-78f4d51fbc78
DOI
10.21203/rs.3.rs-4273109/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 11 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety of rituximab biosimilar (Riximyo®) following a single switch from the reference product in patients with Non-Hodgkin’s Lymphoma: A Retrospective StudyDOI 10.21203/rs.3.rs-4273109/v1
The importance of real-world data in evaluating the safety of biosimilars: a descriptive study of clinical practice in an oncohematological population.Semantic proximity
Continuous effectiveness and safety after a hospital-wide switch to adalimumab biosimilar: an observational study in rheumatoid arthritis patientsSemantic proximity
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myelomaSemantic proximity
Comparison of the inhibitory effects between bepotastine and diphenhydramine on rituximab-induced infusion-related reactions: A single-center retrospective studySemantic proximity
Effectiveness of Switching CGRP monoclonal antibodies in non-responder patients in the UAE: A retrospective studySemantic proximity
Investigation of Patient Satisfaction with Education in a Biosimilar Multiswitch Scenario - A Comparison Between Rheumatologists and Nurse SpecialistsSemantic proximity
Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience.Semantic proximity
Efficacy and Tolerability of Generic Pirfenidone After Switch from Esbriet® in Idiopathic Pulmonary Fibrosis: A Real-World Observational StudySemantic proximity
Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort studySemantic proximity
Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis.Semantic proximity
Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.Semantic proximity
Select a neighboring publication to make it the new centre.